Human Papillomavirus

HspE7 Trial in HPV-Related Anal Dysplasia Initiated

Published in Cancer Weekly, November 28th, 2000

StressGen Biotechnologies Corp. (SSB), Victoria, British Columbia, announced that it has initiated patient treatment in a Phase III clinical trial to investigate HspE7 as an immunotherapeutic for anal dysplasia (AIN) caused by the human papillomavirus (HPV).

HPV is one of the most common sexually-transmitted diseases (STDs) in the world. StressGen also has active Phase II HspE7 studies in women with HPV-related cervical dysplasia and cervical cancer, and plans to initiate a Phase II study in genital warts.

The company previously reported preliminary data from the first patients in its open label Phase II trial in anal dysplasia at two scientific...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry